Author(s): Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, et al.
Objective:To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b treatment in patients with a first clinical event suggestive of multiple sclerosis (MS) (clinically isolated syndrome).
Methods:We conducted a multicenter, randomized, double-blind, placebo-controlled trial. Patients with a first clinical demyelinating event and at least two clinically silent brain MRI lesions were randomized to interferon beta-1b (IFNB-1b) 250 mug subcutaneously (SC) every other day (EOD) (n = 292) or placebo (n = 176), until clinically definite MS (CDMS) was diagnosed or they had been followed for 24 months.
Results:After 2 years, 45% of placebo patients had converted to CDMS (Kaplan-Meier estimate; primary outcome measure) and 85% fulfilled the McDonald criteria (co-primary outcome measure). Overall interferon beta-1b delayed the time to diagnosis of CDMS (p < 0.0001) and McDonald MS (p < 0.00001). Hazard ratios (95% CI) were 0.50 (0.36 to 0.70) for CDMS and 0.54 (0.43 to 0.67) for McDonald MS favoring treatment with IFNB-1b. Treatment was well tolerated, as indicated by the low rate of patients dropping out of the study before CDMS was reached (6.6% overall, 7.2% in the IFNB-1b group).
Conclusions:Interferon beta-1b 250 mug subcutaneously every other day delayed conversion to clinically definite multiple sclerosis, and should be considered as a therapeutic option in patients presenting with a first clinical event suggestive of multiple sclerosis.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/16914693
Author(s): Filippi M, Horsfield MA, Morrissey SP, MacManus DG, Rudge P, et al.
Author(s): Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, et al.
Author(s): Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM et al.
Author(s): Chang CH, Cella D, Fernández O, Luque G, de Castro P, et al.
Author(s): Badia X, Roset M, Montserrat S, Herdman M, Segura A
Author(s): Tintoré M
Author(s): Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, et al.
Author(s): Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, et al.
Author(s): Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O’Connor PW, et al.
Author(s): Miller D, Barkhof F, Montalban X, Thompson A, Filippi M
Author(s): Williams GC, Rodin GC, Ryan RM, Grolnick WS, Deci EL
Author(s): Nortvedt MW, Riise T, Myhr KM, Nyland HI
Author(s): Rudick RA, Miller DM
Author(s): Kappos L, Freedman MS, Polman CH, Edan G, Hartung H-P, et al.
Author(s): Zivadinov R, Zorzon M, Tommasi MA, Nasuelli D, Bernardi M, et al.
Author(s): Sandberg-Wollheim M, Frank D, Goodwin TM, Giesser B, Lopez-Bresnahan M, et al.
